Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN

医学 乙型肝炎 中止 内科学 胃肠病学 不利影响 乙型肝炎表面抗原 乙型肝炎病毒 HBcAg 免疫学 病毒学 病毒
作者
Hélène Fontaine,Sandrine Kahi,C Chazallon,Maryline Bourgine,Anne Varaut,C Buffet,Ophélie Godon,Jean–François Méritet,Y Saïdi,Marie‐Louise Michel,Daniel Scott‐Algara,J.-P. Aboulker,Stanislas Pol
出处
期刊:Gut [BMJ]
卷期号:64 (1): 139-147 被引量:111
标识
DOI:10.1136/gutjnl-2013-305707
摘要

OBJECTIVE: The antiviral efficacy of nucleos(t)ide analogues whose main limitation is relapse after discontinuation requires long-term therapy. To overcome the risk of relapse and virological breakthrough during long-term therapy, we performed a phase I/II, open, prospective, multicentre trial using a HBV envelope-expressing DNA vaccine. DESIGN: 70 patients treated effectively with nucleos(t)ide analogues for a median of 3 years (HBV DNA <12 IU/mL for at least 12 months) were randomised into two groups: one received five intramuscular injections of vaccine (weeks 0, 8, 16, 40 and 44) and one did not receive the vaccine. Analogues were stopped after an additional 48 weeks of treatment in patients who maintained HBV DNA <12 IU/mL with no clinical progression and monthly HBV DNA for 6 months. The primary endpoint was defined as viral reactivation at week 72 (HBV DNA >120 IU/mL) or impossibility of stopping treatment at week 48. RESULTS: Reactivation occurred in 97% of each group after a median 28 days without liver failure but with an HBV DNA <2000 IU/mL in 33%; 99% of adverse reactions were mild to moderate. Immune responses were evaluated by enzyme-linked immunosorbent spot and proliferation assays: there was no difference in the percentage of patients with interferon-γ secreting cells and a specific T-cell proliferation to HBcAg but not to HBsAg after reactivation in each group. CONCLUSIONS: Although it is fairly well tolerated, the HBV DNA vaccine does not decrease the risk of relapse in HBV-treated patients or the rate of virological breakthrough, and does not restore the anti-HBV immune response despite effective viral suppression by analogues. TRIAL REGISTRATION NUMBER: NCT00536627.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
烟花的应助被科研通管家采纳,获得10
1秒前
江江的应助被科研通管家采纳,获得10
1秒前
Zhou完成签到,获得积分20
1秒前
华仔的应助被科研通管家采纳,获得10
1秒前
1秒前
无极微光的应助被科研通管家采纳,获得20
1秒前
JamesPei的应助被科研通管家采纳,获得10
1秒前
cyy完成签到,获得积分10
1秒前
Owen的应助被科研通管家采纳,获得10
1秒前
1秒前
2秒前
zhonglv7的应助被科研通管家采纳,获得10
2秒前
无极微光的应助被科研通管家采纳,获得20
2秒前
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
2秒前
淡淡完成签到,获得积分10
2秒前
斯文败类的应助被科研通管家采纳,获得10
2秒前
2秒前
小虫完成签到,获得积分10
2秒前
kdqiu的应助被yyx采纳,获得10
3秒前
三岁半完成签到,获得积分10
3秒前
4秒前
zzzzz完成签到 ,获得积分10
4秒前
田様的应助被大大魏硕士采纳,获得10
4秒前
momo完成签到,获得积分10
5秒前
5秒前
Maestro_S的应助被Zhou采纳,获得10
6秒前
6秒前
科研通AI6.3的应助被魏伯安采纳,获得10
7秒前
7秒前
7秒前
8秒前
9秒前
10秒前
一抹火烧云完成签到,获得积分10
10秒前
深情安青的应助被奔跑少年采纳,获得10
10秒前
欢喜灵13发布了新的文献求助10
11秒前
感谢大家发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181949
求助须知:如何正确求助?哪些是违规求助? 9571702
关于积分的说明 21819272
捐赠科研通 7778399
什么是DOI,文献DOI怎么找? 3433572
关于科研通互助平台的介绍 2557769
邀请新用户注册赠送积分活动 2479630